The document outlines proposed revisions (2022–2024) by U.S. Food and Drug Administration (FDA) to its human-subjects and IRB regulations (21 CFR 50, 56, and 812), aiming to harmonize FDA rules with the revised Common Rule — including updates to informed-consent requirements (e.g., adding a “key information” summary up front), expanding consent content (e.g., future use of biospecimens), clarifying definitions (e.g., biospecimen/identifiable information), adjusting IRB membership and record-keeping rules, and modifying continuing-review and consent-documentation provisions.
Download